CTLA4 and melanoma: Anti-CTLA-4 antibody ipilimumab was the first drug to show a significant improvement in overall survival in the treatment of advanced melanoma, and its use in this setting was approved in 2011 by the Food and Drug Administration (FDA) (10, 11).